{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000052","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.083400+00:00","generated_at":"2026-05-20T01:12:37.839159+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"AnaptysBio rosnilimab Phase 2b RA data shows best-in-disease profile with JAK-like efficacy","bullets":["424-patient Phase 2b trial: rosnilimab achieved JAK-like efficacy on CDAI LDA, remission, and ACR70 through six months.","Favorable safety: no treatment-related SAEs, <2% discontinuation due to AEs, low injection site reactions.","Responses durable for at least 2 months off drug; pain VAS improved ~50 points from baseline ~65 to ~15.","69% of patients achieved CDAI LDA by Week 14; max response rates not yet observed due to strict continuation criteria."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000052","json":"https://secwatch.observer/filing/0001370053-25-000052.json","markdown":"https://secwatch.observer/filing/0001370053-25-000052.md","text":"https://secwatch.observer/filing/0001370053-25-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000052/0001370053-25-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000052/anab-20250603.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:12:37.839159+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}